2 active not recruiting, 2 temporarily not available, 2 terminated. 3 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Monopar Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors MNPR-101-PCTA-177Lu - Solid Tumor, Adult, Bladder Cancer | Phase 1 | Active not recruiting | Monopar Therapeutics | 12 | 2024-10-08 | 2026-09-03 |
| Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors MNPR-101-DFO*-89Zr, PET/CT Diagnostic Imaging - Solid Tumor, Adult, Bladder Cancer | Phase 1 | Active not recruiting | Monopar Therapeutics | 12 | 2024-05-30 | 2026-09-03 |
| Camsirubicin + Pegfilgrastim to Determine MTD in ASTS Camsirubicin - Advanced Soft-tissue Sarcoma | Phase 1 | Terminated | Monopar Therapeutics | 14 | 2021-09-22 | 2024-05-16 |
| Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet - Chemoradiotherapy-Induced Severe Oral Mucositis | Phase 2 / Phase 3 | Terminated | Monopar Therapeutics | 190 | 2021-02-11 | 2023-05-31 |
| MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer MNPR-101-DFO*-89Zr - Cancer, Solid Tumor | Temporarily not available | Monopar Therapeutics | 2026-09-04 | |||
| MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer MNPR-101-PCTA-177Lu - Cancer, Solid Tumor | Temporarily not available | Monopar Therapeutics | 2026-09-04 |
Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2) · Head and Neck Neoplasms (1) · Mucositis (1) · Oral Ulcer (1) · Oropharyngeal Neoplasms (1) · Sarcoma (1) · Stomatitis (1)
United States (4) · Australia (2) · France (1) · Germany (1) · Puerto Rico (1) · Spain (1)
Ebrahim S. Delpassand, M.D. Chairman & Medical Director, Nuclear Medicine (2) · Holli Carlson (2) · Prof. Rod Hicks, MD (1)